MY ACCOUNT | NEWSLETTER |

Orthopedic applications of 3D printing in canine veterinary medicine


Objective

This case series investigates the application of 3D printing in veterinary orthopedic surgeries, emphasizing its potential to enhance preoperative planning, intraoperative precision, and postoperative outcomes.

Animals

Three canines—German Shepherd, Basset Hound, and Labrador Retriever—were included in this study.

Materials and methods: Three canine cases involving complex orthopedic deformities were selected to illustrate different uses of 3D printing in veterinary surgery. CT scans were segmented using Materialise Mimics 26.0, followed by virtual surgical planning and creation of 3D printed models and guides.

Results

In Case 1, a 2-year-old German Shepherd with a congenital right tibial deformity underwent successful surgical correction aided by a preoperatively prepared external fixator frame, saving approximately 1 h of OR time. In Case 2, a 1-year-old Basset Hound with a left antebrachial deformity had a double wedge osteotomy performed with the assistance of patient-specific cutting and reconstruction guides, leading to optimal alignment and reduced surgical time. Case 3 involved a young, less than 1-year-old Labrador Retriever rescue with severe bilateral tibiofemoral deformity, where 3D printed models helped the surgeon determine that surgery was not the best option, potentially preventing a poor outcome.

Clinical relevance

This case series highlights the transformative potential of 3D printing in veterinary orthopedic surgery, illustrating its ability to improve aid surgical outcomes, reduce operative times, and be a valuable tool in preoperative decision-making. This technology allows for tailored surgical interventions, enhancing the precision and effectiveness of treatment plans in veterinary medicine.


Read the full article here.


Authors: Claire Thomas, Pierre Amsellem, David Nascene, Yu-Hui Huang

Source: https://www.frontiersin.org/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Undergrad researchers drive discovery in the College of Veterinary Medicine

Like0
Dislike0

Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership

Like0
Dislike0

Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study

Like0
Dislike0

Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis

Like0
Dislike0

Insights in the Development and Uses of Alternatives to Antibiotic Growth Promoters in Poultry and Swine Production

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top